CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Nurix Says Sanofi Halts Phase 1 Trial of STAT6 Degrader SAR448272

By Public Technologies
  • Nurix Therapeutics announced Sanofi’s decision to discontinue the Phase 1 trial of oral STAT6 degrader SAR448272 and terminate the program.
  • The termination eliminates expected future development, regulatory and commercial milestone payments or royalties from SAR448272.
  • Milestone and royalty eligibility remains intact for other licensed Sanofi collaboration programs, subject to Sanofi’s development decisions.
  • Cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, support unchanged funding guidance into second-half 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031601PRIMZONEFULLFEED9869385) on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk